EUVIMEDEUVIMED entdecken
VergleichsstudieBeobachtungsstudieOpen Access · CC BY 4.0

Comparative Analysis of Antithrombotic Strategies Following Valve-in-Valve Transcatheter Aortic Valve Implantation Using Real-World Registry Data

Edward Dababneh, Maria Gabriela Matta, Ajay Sinhal, Selvanayagam Niranjan, Sylvio Provenzano, Anthony Camuglia, Ian Hughes, Kuljit Singh

Cardiovascular Drugs and Therapy · 2026-12 · 40 (6) · 2303-2314

DOI: 10.1007/s10557-026-07914-2 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cardiovascular Drugs and Therapy, online erschienen am 17.07.2026. Verfasst von Edward Dababneh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Gold Coast Health Service, Gold Coast, QLD, Australia. Hauptthemen laut MEDLINE: Transcatheter Aortic Valve Replacement, Platelet Aggregation Inhibitors, Anticoagulants, Fibrinolytic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Griffith University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Valve-in-valve transcatheter aortic valve implantation is a less invasive alternative to redo surgery for failed surgical bioprostheses, but optimal antithrombotic management is uncertain.

Objectives

To compare outcomes across antithrombotic regimens after valve-in-valve procedures in real-world practice.

Methods

In the Australasian Cardiac Outcomes Registry (2018–2025), 1,050 adults were grouped by discharge regimen: single antiplatelet therapy, dual antiplatelet therapy, oral anticoagulation, or oral anticoagulation plus antiplatelet therapy. Outcomes included 30-day and 12-month mortality, stroke/TIA, life-threatening or major bleeding, major adverse cardiac and cerebrovascular events, and echocardiographic valve performance.

Results

Thirty-day mortality was higher with oral anticoagulation (1.7%) and combination therapy (3.6%) than with single or dual antiplatelet therapy (both 0%; p < 0.001). The 30-day MACCE rate was greater with oral anticoagulation (4.5%) and combination therapy (4.4%) than with single (1.5%) or dual antiplatelet therapy (0.4%) ( p = 0.003); stroke/TIA and bleeding were infrequent and similar across groups. At 12 months, MACCE remained highest with oral anticoagulation (11.8%) and combination therapy (10.7%) compared with single (5.0%) and dual antiplatelet therapy (3.2%) ( p = 0.001). Mortality at 12 months was numerically higher with oral anticoagulation or combination therapy (5.2% and 4.4%) than with single or dual antiplatelet therapy (1.8% and 2.4%) ( p = 0.116). At 30 days, transvalvular gradients were lower in patients receiving oral anticoagulation-containing regimens; however, no significant differences in gradients, valve area, ejection fraction, or regurgitation were observed at 12 months. In multivariable analysis, combination therapy was independently associated with higher odds of 12-month MACCE compared with SAPT (OR 2.76, 95% CI 1.03–7.37; p = 0.043). Higher STS score and greater frailty were also independently associated with 12-month MACCE.

Conclusions

In this observational cohort of patients undergoing valve-in-valve TAVI, oral anticoagulation-containing regimens were associated with higher early mortality and higher 12-month MACCE rates than antiplatelet-only strategies. However, these associations should be interpreted cautiously, as they likely reflect in part the greater baseline comorbidity burden of patients prescribed anticoagulation rather than a direct treatment effect. No sustained haemodynamic benefit was observed at 12 months. Individualised antithrombotic therapy and prospective randomised studies are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transcatheter Aortic Valve ReplacementPlatelet Aggregation InhibitorsAnticoagulantsFibrinolytic AgentsAortic ValveAortic Valve StenosisHumansRegistriesFemaleMaleAged, 80 and overAgedTreatment OutcomeHemorrhageAdministration, OralRisk FactorsHeart Valve ProsthesisDrug Therapy, CombinationTime FactorsDual Anti-Platelet Therapy

Stichwörter der Autor:innen

AntithromboticOral anticoagulationViV TAVI

Substanzen

Platelet Aggregation InhibitorsAnticoagulantsFibrinolytic Agents

Autor:innen und Institutionen

  • Department of Cardiology, Gold Coast Health Service, Gold Coast, QLD, Australia.
  • Department of Medicine, Griffith University School of Medicine, Gold Coast, QLD, Australia.
  • Department of Cardiology, Flinders Medical Centre, Adelaide, South Australia, Australia.
  • Department of Medicine, University of Adelaide, Adelaide, SA, Australia.
  • Department of Medicine, Bond University, Gold Coast, QLD, Australia.
  • Department of Cardiology, Princess Alexandra Hospital, Woolangabba, QLD, Australia.

Förderung

  • Griffith University

Zitieren

APA

Dababneh, E., Matta, M. G., Sinhal, A., Niranjan, S., Provenzano, S., Camuglia, A., Hughes, I., & Singh, K. (2026). Comparative Analysis of Antithrombotic Strategies Following Valve-in-Valve Transcatheter Aortic Valve Implantation Using Real-World Registry Data. Cardiovascular Drugs and Therapy, 40(6), 2303-2314. https://doi.org/10.1007/s10557-026-07914-2

Vancouver

Dababneh E, Matta MG, Sinhal A, Niranjan S, Provenzano S, Camuglia A, et al. Comparative Analysis of Antithrombotic Strategies Following Valve-in-Valve Transcatheter Aortic Valve Implantation Using Real-World Registry Data. Cardiovascular Drugs and Therapy. 2026;40(6):2303-2314. doi:10.1007/s10557-026-07914-2

BibTeX
@article{Dababneh2026,
  author = {Dababneh, Edward and Matta, Maria Gabriela and Sinhal, Ajay and Niranjan, Selvanayagam and Provenzano, Sylvio and Camuglia, Anthony and Hughes, Ian and Singh, Kuljit},
  title = {Comparative Analysis of Antithrombotic Strategies Following Valve-in-Valve Transcatheter Aortic Valve Implantation Using Real-World Registry Data},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2026},
  volume = {40},
  number = {6},
  pages = {2303--2314},
  doi = {10.1007/s10557-026-07914-2}
}
Kostenlos starten →